Psoriasis [2026]: Causes, Triggers, and Prescription Treatment Options

Last updated: September 23, 2026 Reviewed by PrescribedGlow Editorial Team, Editorial

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. Our editorial opinions are our own.

Psoriasis is a chronic, immune-mediated inflammatory skin condition characterized by accelerated keratinocyte turnover, producing thick, erythematous plaques covered in silvery scales. Driven by dysregulated IL-23 and IL-17 cytokine signaling, it is aggravated by stress, skin trauma, and infections. While incurable, modern prescription treatments—including non-steroidal topicals, tazarotene, and biologics—provide rapid, sustained disease control.

Affiliate Disclosure: PrescribedGlow is supported by our readers. When you purchase prescription treatments through links on our site, we may earn an affiliate commission at no extra cost to you.

Clinical Feature Plaque Psoriasis Atopic Dermatitis (Eczema) Seborrheic Dermatitis
Lesion Appearance Thick, well-demarcated plaques with silvery scales Ill-defined, dry, excoriated, lichenified patches Greasy, yellowish scales over erythematous patches
Common Distribution Extensor surfaces (elbows, knees), scalp, lower back Flexural creases (inner elbows, behind knees), neck Sebum-rich zones (scalp, eyebrows, nasolabial folds)
Primary Mechanism Autoimmune IL-23/IL-17 cytokine cascade Epidermal barrier defect (FLG) & Th2 inflammation Malassezia yeast proliferation & sebum reaction
Itch & Sensation Mild-to-moderate burning, stinging, or soreness Intense, unrelenting, sleep-disrupting pruritus Mild itching, flaking, or superficial irritation
Auspitz Sign Positive (pinpoint bleeding when scales peel) Negative (oozing or crusting without pinpoint bleed) Negative (scales peel without vascular exposure)

What is the difference between psoriasis and eczema?

The primary clinical difference between psoriasis and eczema is their lesion appearance, typical anatomical distribution, and immune mechanism. Psoriasis produces thick, sharply demarcated plaques capped by silvery scales on extensor surfaces like elbows and knees. In contrast, eczema (atopic dermatitis) forms ill-defined, dry, intensely itchy patches localized primarily in flexural skin creases.

In plaque psoriasis, rapid keratinocyte accumulation produces the hallmark Auspitz sign: gentle scraping of adherent scales reveals microscopic pinpoint bleeding from dilated superficial capillaries. Conversely, atopic dermatitis (eczema) stems from epidermal barrier defects often linked to filaggrin gene mutations, resulting in severe itch and weeping lesions. Similarly, seborrheic dermatitis concentrates in oily facial folds and scalp areas, caused by inflammatory reactions to Malassezia yeast rather than autoimmune hyperproliferation.

Psoriasis represents a substantial public health burden. In a population-based study published in JAMA Dermatology (Armstrong et al., 2021; PMID: 34190957), researchers analyzed NHANES data and determined that psoriasis affects approximately 3.0% of the U.S. adult population (roughly 7.55 million adults), including 3.2% of women and 2.8% of men.

What causes psoriasis flare-ups?

Psoriasis flare-ups occur when external triggers or internal stressors activate pro-inflammatory cytokine pathways in genetically predisposed individuals. Key catalysts include psychological stress, physical skin injury, streptococcal infections, cold dry weather, smoking, alcohol use, and certain prescription drugs.

In susceptible skin, dendritic cells stimulate T-helper 17 (Th17) lymphocytes to release interleukin-23 (IL-23) and interleukin-17 (IL-17). These cytokines accelerate keratinocyte turnover, compressing their maturation cycle from 28 days down to 3 to 5 days.

Common triggers include:

  • The Koebner Phenomenon: Mechanical trauma—cuts, scratches, tattoos, or sunburns—causes new plaques to form along the injury site within 10 to 14 days.
  • Psychological Stress: Elevated cortisol and substance P activate neurogenic inflammation, triggering flare-ups.
  • Systemic Infections: Streptococcal pharyngitis (strep throat) frequently precipitates guttate psoriasis, presenting as widespread small drop-like scaly spots.
  • Cold Climates: Low-humidity winter air dehydrates the stratum corneum, weakening barrier defenses.
  • Medications: Beta-blockers, lithium, and antimalarials can provoke or exacerbate plaque flares.

Resolved plaques often leave behind temporary dark marks known as post-inflammatory hyperpigmentation. Additionally, patients with chronic scaly conditions may also develop rough follicular bumps like keratosis pilaris on the extremities.

What is the most effective prescription treatment for psoriasis?

The most effective prescription treatment depends on plaque severity, affected body surface area (BSA), and anatomical location. For localized disease (under 10% BSA), topical therapies—including potent corticosteroids, vitamin D analogs, tazarotene, and novel non-steroidal agents like roflumilast and tapinarof—deliver high clearance rates without systemic risks.

Topical Corticosteroids and Vitamin D Analogs

Potent topical corticosteroids (such as clobetasol propionate or betamethasone dipropionate) quickly suppress localized inflammation. However, continuous application risks skin thinning (atrophy), telangiectasias, and tachyphylaxis. To maintain remission safely, clinicians frequently alternate steroids with vitamin D3 analogs like calcipotriene, which slows keratinocyte proliferation and promotes normal differentiation.

Topical Retinoids: Tazarotene

Tazarotene is a receptor-selective third-generation retinoid approved for plaque psoriasis and acne. By selectively binding retinoic acid receptors beta and gamma, it normalizes epidermal differentiation and reduces plaque thickness. As detailed in our guide on tazarotene vs tretinoin, modern 0.045% lotion formulations and fixed combinations with halobetasol provide powerful anti-inflammatory clearance with improved tolerability.

Next-Generation Non-Steroidal Topicals

Recent pharmaceutical advances have introduced targeted, non-steroidal topicals safe for long-term daily use on both body plaques and sensitive skin folds:

  • Roflumilast 0.3% Cream (Zoryve): A selective phosphodiesterase-4 (PDE4) inhibitor that dampens intracellular inflammatory signaling. In two Phase 3 trials in JAMA (Lebwohl et al., 2022; PMID: 36125472) encompassing 881 patients (DERMIS-1 and DERMIS-2), 42.4% and 37.5% of patients achieved IGA treatment success (clear or almost clear skin) at Week 8 with once-daily roflumilast cream, compared to 6.1% and 6.9% for vehicle ($p < 0.001$).
  • Tapinarof 1% Cream (Vtama): A first-in-class topical aryl hydrocarbon receptor (AhR) agonist that downregulates IL-17 and restores skin barrier proteins. In two Phase 3 trials in the New England Journal of Medicine (Lebwohl et al., 2021; PMID: 34882976) with 1,025 patients (PSOARING 1 and 2), 35.4% and 40.2% achieved PGA success at Week 12 vs 6.0% and 6.3% on vehicle ($p < 0.001$), demonstrating a remittive benefit lasting months off-treatment.

Systemic Biologics and Oral Therapies

For moderate-to-severe psoriasis covering over 10% BSA, systemic therapies provide targeted immune control. Modern biologics neutralizing IL-23 (guselkumab, risankizumab) or IL-17 (secukinumab, ixekizumab) achieve high rates of complete skin clearance, while oral PDE4 inhibitors (apremilast) provide non-steroidal systemic management.

Can you get prescription psoriasis treatment online?

Yes, patients can obtain professional clinical evaluations and prescription psoriasis treatments online through teledermatology platforms like Honeydew Care, Ro Derm, and Nurx. Board-certified dermatologists and licensed clinicians examine photos of your skin, evaluate flare severity, and electronically prescribe targeted topicals or maintenance regimens delivered directly to your home.

Virtual dermatology clinics serve different treatment needs:

  • Medical Dermatology (Honeydew Care): As detailed in our Honeydew vs Curology comparison, Honeydew Care functions as a full-service virtual clinic specializing in chronic conditions like psoriasis and eczema, managing prescription regimens and navigating health insurance.
  • Custom Compounded Formulas (Ro Derm & Dermatica): Ro Derm and Dermatica offer asynchronous photograph reviews and prescribe tailored anti-inflammatory creams for home delivery.
  • Affordable Generic Prescriptions (Nurx): Nurx offers digital consultations for common rashes, processing commercial insurance for generic topical corticosteroids and calcipotriene.

To learn how asynchronous photographic consultations operate, read our guide on how online dermatology works. If you are pregnant or nursing, note that topical retinoids like tazarotene are contraindicated; explore our overview of pregnancy-safe skincare for safe alternatives.

Clinical Note: If psoriasis covers extensive body areas, causes painful joint stiffness, or involves pustules and fever, seek an in-person medical evaluation immediately.

Frequently asked questions

What is the difference between psoriasis and eczema? Psoriasis causes sharply demarcated, thick, red plaques covered with silvery scales, typically on extensor surfaces like elbows and knees. Eczema (atopic dermatitis) causes ill-defined, dry, intensely itchy, weeping patches that primarily appear in flexural creases like the inner elbows and behind the knees.

What causes psoriasis flare-ups? Psoriasis flares are triggered when internal or environmental stressors provoke an overactive immune cascade in genetically predisposed skin. Common triggers include emotional stress, physical skin injury (Koebner phenomenon), streptococcal infections, dry winter weather, smoking, alcohol consumption, and medications like beta-blockers or lithium.

What is the best prescription treatment for psoriasis? The best treatment depends on plaque severity, location, and body surface area. Mild-to-moderate plaques respond well to topical treatments, including high-potency corticosteroids, calcipotriene, tazarotene, and next-generation non-steroidal topicals like roflumilast and tapinarof. Widespread or resistant disease typically requires phototherapy or targeted systemic biologics.

Can psoriasis be cured permanently? No, psoriasis cannot be permanently cured because it is a lifelong, genetically mediated autoimmune condition driven by IL-23 and IL-17 immune signaling. However, modern targeted prescription therapies enable patients to achieve complete or near-complete skin clearance and maintain long-term symptom-free remission.

Can you get prescription psoriasis treatment online? Yes, telehealth dermatology platforms like Honeydew Care, Ro Derm, and Nurx evaluate psoriasis online. Licensed clinicians and board-certified dermatologists review photos of your skin, assess flare severity, and prescribe FDA-approved non-steroidal topicals, steroid-sparing creams, or maintenance regimens delivered directly to your doorstep.

Is psoriasis an autoimmune disease? Yes, psoriasis is classified as a chronic, immune-mediated inflammatory disease. The immune system mistakenly accelerates skin cell turnover, causing keratinocytes to mature and migrate to the surface in just 3 to 5 days instead of the normal 28 to 30 days, creating thick, raised plaques.

Bottom line

Psoriasis is a chronic, immune-mediated condition characterized by accelerated epidermal cell turnover and IL-23/IL-17 inflammation. While OTC moisturizers offer foundational barrier hydration, controlling inflammatory plaques requires targeted prescription care. With innovative non-steroidal topicals like roflumilast and tapinarof, alongside selective retinoids like tazarotene, patients can achieve durable skin clearance without the risks of steroid-induced skin thinning.

Explore our Honeydew vs Curology comparison · Read our Ro Derm review · Read our Dermatica review · Read our Nurx review

Sources

  • Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatology. 2021;157(8):940-946. PMID: 34190957. https://pubmed.ncbi.nlm.nih.gov/34190957/
  • Lebwohl MG, Kircik LH, Moore AY, et al. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. JAMA. 2022;328(11):1073-1084. PMID: 36125472. https://pubmed.ncbi.nlm.nih.gov/36125472/
  • Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. New England Journal of Medicine. 2021;385(24):2219-2229. PMID: 34882976. https://pubmed.ncbi.nlm.nih.gov/34882976/